CDC42 and metastatic prostate carcinoma: ZCL278 is another selective Cdc42 small-molecule inhibitor that blocks the binding of Cdc42 to intersectin, thereby suppressing actin-based motility and migration in metastatic prostate cancer cells [136,137].